Sanofi’s next-generation long-acting basal insulin Toujeo will enter a challenging commercial market when it launches in April, going up against Sanofi’s own Lantus, securely entrenched as the gold standard.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?